Apply to trial NCT07604571

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 1Drug trial

Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

The purpose of this study is to evaluate the safety, tolerability and preliminary activity of IEV407 as a single agent and in combination with endocrine therapy (fulvestrant or letrozole) in patients with advanced hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-negative) breast cancer.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening